Maximize Your Involvement in the OTS Community
Presenter: Erin M. McConnell, Ph.D.,University of Ottawa Annemieke Aartsma-Rus, PhD, OTS President,Leiden University Medical Center Date: June 24, 2021 Time: 8am Pacific/11am Eastern/5pm Central European Time Description: Do you study how oligonucleotides can be used as therapeutics? Are you new to the OTS? ...
How to test for immune activation by your therapeutic oligonucleotide
Presenter: Arthur M. Krieg, MD, Checkmate Pharmaceuticals Date: 19 April 2018 Description: RNA and DNA oligonucleotides with charged backbones commonly cause immune activation, which can be recognized by appropriate in vitro and/or in vivo testing. Eukaryotic innate immune systems have evolved multiple receptors to ...
Designing siRNAs for improving their therapeutic applications
Presenter: Dr. Annabelle Biscans (AstraZeneca) Date: January 27th, 2021 Description: Small interfering RNAs (siRNAs) have the potential to revolutionize medicine due to their potency, duration of effect, and ability to target previously “undruggable” disease genes. The clinical success of siRNAs is dependent on their ...
Making medicines out of pre-mRNA splicing modulators
Presenter: Isabel Aznarez, Ph.D. Stoke Therapeutics Date: April 29th, 2021 Description: Splicing is the process that edits precursor-messenger RNA (pre-mRNA) to generate the messenger RNA (mRNA) that carries the code from the nucleus to the cytoplasm where the ribosomes will translate it into a ...
The N-Lorem Foundation
Presenter: Stanley T. Crooke, MD, PhD Ionis Pharmaceuticals Date: February 9th, 2021 Description: The purpose of this presentation is to formally introduce n-Lorem to OTS and to summarize progress since being founded in January 2020. Recording of the webinar: Click play to view ...
Academia or Industry? A career discussion
Presenter: Prof. Annemieke Aartsma-Rus, (OTS President; Leiden University Medical Center) and Dr. Shalini Andersson (Chief Scientist New Therapeutic Modalities and Head of Oligonucleotide Discovery, AstraZeneca) Date: July 15, 2020 Description: To start off, Prof. Annemieke Aartsma-Rus (OTS President; Leiden University Medical Center) and Dr. ...
Time matters! – Why PK/PD is important for oligo development
Presenter: Carl Amilon (AstraZeneca) Date: June 10, 2020 Description: This webinar will give an overview of how incorporating quantitative PK/PD aspects of an oligonucleotide will help you designing more informative experiments and help in translating to a human. We have all struggled with questions around the ...
Safety of Therapeutic Oligonucleotides
Presenter: Patrik Andersson (AstraZeneca) Date: May 13, 2020 Description: Successful therapeutics need to be efficacious and safe. Although oligonucleotide therapeutics act via unique mechanisms, they follow the same principles for safety assessment as other modalities. This webinar will give an overview of these principles and what ...
Delivery of Macromolecular Therapeutics: Tackling a Billion Year Old Barrier
Presenter: Steven Dowdy (UCSD School of Medicine) Date: December 17, 2019 Description: All macromolecular therapeutics, including ASOs, siRNAs, peptides, proteins, CRISPR, mRNA and non-viral DNA vectors, are taken up into cells by endocytosis. However, <1% to none of the endocytosed therapeutic cargo escapes into the cytoplasm ...
Circular RNA Immunity
Presenter: Grace Chen (Yale School of Medicine) Date: March 25, 2020 Description: Circular RNAs are a newly appreciated class of ubiquitous and abundant RNAs. In the webinar, we will cover biological and chemical approaches to synthesize circular RNAs, how cells distinguish between endogenous and foreign circular RNAs, ...
